Group 1 - The core viewpoint of the article highlights that Baoyi Pharmaceutical-B (02659) successfully completed a new share issuance of approximately HKD 1 billion, attracting significant attention in the capital market with a particularly enthusiastic response from investors [1] - The IPO international placement was oversubscribed by 6.59 times, while the Hong Kong public offering saw an impressive 3526.34 times subscription, indicating high market participation [1] - Baoyi Pharmaceutical is expected to officially list on the Hong Kong Stock Exchange on December 10, 2025, with strong initial trading performance reflected in the dark market, where shares were priced at HKD 56, a 112.28% increase from the offering price of HKD 26.38 [1] Group 2 - The company has attracted several well-known institutional cornerstone investors, including Anke Biotechnology Hong Kong and Guotai Junan Securities Investment, who collectively subscribed for HKD 200.6 million, accounting for approximately 20.06% of the total funds raised [1] - Baoyi Pharmaceutical is a biotechnology company in the clinical and commercialization stages, focusing on developing and providing recombinant biopharmaceuticals in China using synthetic biology technology [2] - The company is targeting four independent and high-value treatment markets, including large-volume subcutaneous administration and antibody-mediated autoimmune diseases, with three core products already in commercialization or late clinical stages [2] Group 3 - The funds raised from the IPO will be allocated to the research and commercialization of core products (KJ017, KJ103, and SJ02), advancing other existing pipeline products, optimizing proprietary synthetic biology technology, and enhancing production capacity [3] - Baoyi Pharmaceutical's financial performance supports its listing, with revenues of RMB 6.93 million, RMB 6.16 million, and RMB 41.99 million for the six months ending June 30 in 2023, 2024, and 2025, respectively, indicating strong growth potential [2] - The company has sufficient cash reserves, with cash and cash equivalents amounting to RMB 453 million as of June 30, 2025, which will support its operational needs and growth initiatives [2]
新股消息 宝济药业-B(02659)IPO受追捧：国际配售获6.59倍认购 长线资本坚定入驻